GlassScriptPhysician profile
Amir H Moasser
NPI 1932102530
$4,949.08
in general payments reported to CMS, 2019-2025
29 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $149 · 2021: $263 · 2022: $731 · 2023: $772 · 2024: $1,200 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499 · Education: $48.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.27 |
| Education | $48.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.40 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $626.45 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $322.53 | 2024-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $306.71 | 2021-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $286.08 | 2020-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $273.01 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $253.32 | 2022-2025 | Injectafer |
| Akebia Therapeutics INC | $240.44 | 2019-2022 | |
| Travere Therapeutics, INC. | $219.50 | 2022-2025 | Filspari |
| Ardelyx, INC. | $195.49 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $174.63 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $167.52 | 2023-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $154.31 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $133.77 | 2021-2024 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $132.04 | 2022-2025 | Jynarque |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.05 | 2024-2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $118.87 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.03 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $75.87 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $70.05 | 2022-2025 | Shingrix, Arexvy, Benlysta |
| Vifor Pharma, INC. | $55.79 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $49.03 | 2022-2023 | |
| Abiomed | $36.80 | 2023 | Impella |
| Takeda Pharmaceuticals U.S.A., INC. | $34.52 | 2024 | Gattex |
| Gilead Sciences, INC. | $32.56 | 2024 | |
| Impulse Dynamics (USA) INC. | $26.19 | 2022 | |
| Cormedix INC. | $20.67 | 2025 | Defencath |
| Fresenius USA Marketing, INC. | $19.90 | 2022 | |
| Shield Therapeutics INC | $17.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Moasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.